OPPM
IMMU

Opus Point Partners Management’s Immunomedics Inc IMMU Stock Holding History

Opus Point Partners Management’s Portfolio IMMU Stock Details IMMU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-62,575
Closed -$868K – 65
2019
Q2 		$868K Hold
62,575
– – 1.28% 18
2019
Q1 		$1.2M Buy
+62,575
New +$1.01M 1.63% 13

Other funds holding IMMU

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

Opus Point Partners Management's IMMU Position: Q3 2019 in Review

Opus Point Partners Management sold out of Immunomedics Inc (IMMU) in Q3 2019, closing a stake of 62,575 shares — an estimated $868K sold.

Opus Point Partners Management first reported a position in IMMU in Q1 2019 and held it in 2 quarters. The position peaked at $1.2M in Q1 2019. 208 funds tracked by Wall St. Rank hold IMMU as of Q3 2019.

  • Opus Point Partners Management reported no remaining Immunomedics Inc position as of Q3 2019 after selling out during the quarter.
  • Opus Point Partners Management sold 62,575 Immunomedics Inc shares in Q3 2019, an estimated $868K.
  • Opus Point Partners Management first reported a position in Immunomedics Inc in Q1 2019 and held it in 2 quarters.
  • Opus Point Partners Management's Immunomedics Inc position peaked at $1.2M in Q1 2019.
  • 208 funds tracked by Wall St. Rank held Immunomedics Inc as of Q3 2019.

Based on Opus Point Partners Management's 13F filing for Q3 2019, filed 14 Nov 2019.